Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Retained Earnings (2016 - 2025)

Enanta Pharmaceuticals' Retained Earnings history spans 14 years, with the latest figure at -$329000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings fell 1034.48% year-over-year to -$329000.0; the TTM value through Dec 2025 reached -$329000.0, down 1034.48%, while the annual FY2025 figure was -$404.9 million, 134182.45% down from the prior year.
  • Retained Earnings reached -$329000.0 in Q4 2025 per ENTA's latest filing, up from -$404.9 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $18.5 million in Q4 2021 to a low of -$404.9 million in Q3 2025.
  • Average Retained Earnings over 5 years is -$81.9 million, with a median of -$1.7 million recorded in 2023.
  • Peak YoY movement for Retained Earnings: skyrocketed 100.15% in 2024, then plummeted 134182.45% in 2025.
  • A 5-year view of Retained Earnings shows it stood at $18.5 million in 2021, then tumbled by 114.49% to -$2.7 million in 2022, then crashed by 8886.99% to -$240.4 million in 2023, then skyrocketed by 99.99% to -$29000.0 in 2024, then plummeted by 1034.48% to -$329000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Retained Earnings are -$329000.0 (Q4 2025), -$404.9 million (Q3 2025), and -$402000.0 (Q2 2025).